Clinical Trial Update: Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer [Phase 1]

View source ↗

Summary

This Phase 1 trial investigates the combination of Bevacizumab, Erlotinib, and Capecitabine for locally advanced rectal cancer. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Tarceva (erlotinib)
• Xeloda (capecitabine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Rectal Cancer | Phase 1 | Status: COMPLETED